San Diego-based biotechnology firm ADARx Pharmaceuticals, Inc. has officially priced its upsized initial public offering (IPO) at $17.00 per share—the ceiling of its previously target range of $15.00 to $17.00.

Strong institutional demand prompted the company to expand the offering from 21.88 million to 26.25 million shares, raising $446.25 million in gross proceeds. The stock debuted on the Nasdaq Global Select Market under the ticker symbol ADRX.
1. Key Offering Terms & Deal Mechanics
- IPO Share Price: $17.00 per share (High end of $15.00 – $17.00 range)
- Total Primary Shares Sold: 26,250,000 shares (Upsized from 21.88M)
- Gross IPO Proceeds: ~$446.25 Million
- Underwriter Greenshoe: 30-day option for up to an additional 3,937,500 shares
- Market Capitalization at Listing: ~$1.81 Billion
- Joint Book-Running Managers: J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, and LifeSci Capital
┌────────────────────────────────────────────────────────────────────────┐
│ ADARX PHARMACEUTICALS (ADRX) IPO │
├─────────────────────────┬──────────────────────────────────────────────┤
│ Metric │ Detail / Value │
├─────────────────────────┼──────────────────────────────────────────────┤
│ Ticker Symbol │ NASDAQ: ADRX │
│ Final Offer Price │ $17.00 per share (High end) │
│ Shares Issued │ 26.25 Million (Upsized from 21.88M) │
│ Direct IPO Capital │ $446.25 Million │
│ Strategic Investment │ $100.00 Million (AbbVie Concurrent Private) │
│ Total Gross Proceeds │ ~$535.25 Million │
│ Initial Debut Trading │ Opened at $22.10 (+30% initial pop) │
└─────────────────────────┴──────────────────────────────────────────────┘
2. Strategic Backing: The AbbVie Partnership
Adding significant credibility to the offering, pharmaceutical giant AbbVie (NYSE: ABBV) purchased $100 million of ADARx common stock in a concurrent private placement at the $17.00 IPO price.
This private placement expands AbbVie’s existing multi-year collaboration with ADARx—focused on developing novel therapies across neuroscience, immunology, and oncology—giving AbbVie a ~4.9% equity stake in the company post-offering. Combined, the IPO and private placement delivered $535.2 million in fresh capital before underwriter option execution.
3. Technology Pipeline: Next-Gen RNA Interference (siRNA)
ADARx is targeting genetic, complement-mediated, and central nervous system disorders using proprietary small interfering RNA (siRNA) platforms designed to silence disease-causing genes before targeted proteins can form.
- Lead Asset — Onvuzosiran (Late-Stage Clinical): An siRNA therapeutic targeting hereditary angioedema (HAE) entering Phase 3 trials. Early clinical trials demonstrated up to a 93% reduction in plasma kallikrein, the protein responsible for severe swelling episodes.
- Agazisiran (Phase 2 Clinical): Targeting complement-mediated diseases, including IgA nephropathy, geographic atrophy, and paroxysmal nocturnal hemoglobinuria.
- Preclinical & Early Pipeline: Next-generation RNAi programs targeted toward metabolic conditions (obesity) and neurodegenerative conditions like Alzheimer’s disease.
4. Market Performance & Biotech Sentiment
The strong pricing and immediate secondary market demand highlight a broader revival in institutional risk appetite for late-stage clinical biotechs:
EXPLORE MORE
Dodgers player calls on MLB to ban ‘soft porn’ commercials
Los Angeles Dodgers outfielder Alex Call took to social media to urge…
Pennsylvania Treasurer Stacy Garrity Exposes Josh Shapiro’s Budget Failures And Vows Major Economic Turnaround
HARRISBURG, Pa. — The political landscape in the Keystone State is shifting…
Labor Shortages Drive Record Bankruptcies in Japan in First Half of Fiscal Year
The number of corporate bankruptcies in Japan caused by labor shortages has…
Rep. Meuser – Small Business Committee Hearing
As lawmakers on Capitol Hill continue to grapple with the economic pressures…
New Klein Adjustable Wrench is Also a Pass-thru Ratchet
The new Klein Tools 2-in-1 adjustable wrench, 5076RT, is pretty self-explanatory. It’s…
U.S. CISA adds Prettier eslint-config-prettier, Vite Vitejs, Versa Concerto SD-WAN orchestration platform, and Synacor Zimbra Collaboration Suite flaws to its Known Exploited Vulnerabilities catalog
U.S. Cybersecurity and Infrastructure Security Agency (CISA) adds Prettier eslint-config-prettier, Vite Vitejs, Versa…
- Trading Debut:
ADRXopened on the secondary market at $22.10, surging 30% above its initial $17.00 offering price before settling around $19.35 on its first day. - Capital Runway: The combined $535M capital injection provides ADARx with runway through late-stage Phase 3 clinical readouts anticipated in 2027.
